Envision Healthcare has inked a deal to acquire Imaging Advantage, a move that will boost its presence in radiology physician services. Financial details were not disclosed.
Formed by AmSurg and Envision’s merger last December, the acquirer provides physician-led services, ambulatory surgery services, post-acute care and medical transportation. Imaging Advantage offers a cloud-based platform connecting more than 500 radiologists across 450 health facilities in 26 states. The transaction is expected to close in the second quarter.
“We believe the merger with Envision creates a valuable, integrated platform for radiologists and leverages our innovative radiology care model,” said Imaging Advantage CEO Naseer Hashim in a statement. “ … The merger will enable us to more effectively preserve and advance the intrinsic and important role of providers in their local communities, while managing relationships with health systems and enhancing service levels for referring physicians.”
“What [Imaging Advantage] does is similar to the business models of Amazon, Airbnb and Uber. We deploy innovative algorithms to match supply and demand in the cloud to turn … waste into value,” Hashim said in a 2015 Forbes interview.
Connecting radiologists and hospitals in its cloud platform gives each facility access to hundreds of physicians, rather than the few each has onsite. This can cut image turnaround times and, in turn, reduce wait times in emergency rooms and a patient’s hospital stay, he said.
In December 2015, Imaging Advantage partnered with RadNet, which operates outpatient radiology centers, to bring cloud-based radiology services to centers across the country.
By Amirah Al Idrus
Source: Fierce Biotech
Hybrid closed-loop systems rely on an algorithm to first analyze real-time blood sugar readings from a continuous glucose monitor, then use the results to adjust an insulin pump’s output as needed throughout the day. In this case, the algorithm was developed by Diabeloop, the CGM is a Dexcom G6 sensor, and the insulin pump comes from ViCentra.
Boehringer Ingelheim has acquired bacterial cancer therapy company T3 Pharmaceuticals in a deal that could be worth up to 450 million Swiss francs ($508 million). The addition of Allschwil, Switzerland-based T3 will “significantly expand” the German drugmaker’s immuno-oncology pipeline and aligns with some of the company’s existing R&D programs.
EuroAPI has completed the acquisition of BianoGMP, a contract development and manufacturing organization (CDMO) specializing in oligonucleotides. The acquisition, announced in August, further differentiates its value proposition to support a broader client base across the whole oligonucleotide development continuum, from research to commercialization, EuroAPI said.